{"id":"NCT00908349","sponsor":"Supernus Pharmaceuticals, Inc.","briefTitle":"Safety and Tolerability of OXC XR as Adjunctive Therapy in Subjects With Refractory Partial Epilepsy","officialTitle":"Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of OXC XR as Adjunctive Therapy in Subjects With Refractory Partial Epilepsy","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-06","primaryCompletion":"2011-11","completion":"2011-11","firstPosted":"2009-05-25","resultsPosted":"2017-05-31","lastUpdate":"2017-05-31"},"enrollment":214,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Partial Epilepsy"],"interventions":[{"type":"DRUG","name":"Oxcarbazepine XR","otherNames":["SPN-804O"]}],"arms":[{"label":"Oxcarbazepine XR","type":"OTHER"}],"summary":"Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of Oxcarbazepine Extended-Release (OXC XR)","primaryOutcome":{"measure":"Percent Change in Seizure Rate","timeFrame":"one year","effectByArm":[{"arm":"Oxcarbazepine XR","deltaMin":-26.3,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":58,"countries":["United States","Bulgaria","Canada","Croatia","Mexico","Poland","Romania","Russia"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":18,"n":214},"commonTop":["Dizziness","Headache","Diplopia","Nausea","Vomiting"]}}